株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

注目市場の分析:汗腺膿瘍

Market Spotlight: Hidradenitis Suppurativa

発行 Datamonitor Healthcare 商品コード 633141
出版日 ページ情報 英文 38 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.11円で換算しております。
注目市場の分析:汗腺膿瘍 Market Spotlight: Hidradenitis Suppurativa
出版日: 2020年02月14日 ページ情報: 英文 38 Pages
概要

当レポートでは、世界の汗腺膿瘍市場について調査し、汗腺膿瘍の概要と治療、上市済みおよび近年のパイプライン薬剤、収益の機会、治験動向などについてまとめています。

概要

疾病概要

治療

疾患概要

  • 汗腺膿瘍サブタイプ

上市済み薬剤

  • 米国のパイプライン薬剤

主な法規制イベント

  • CIのCyltezoが今年15回目のEUバイオシミラー・オブ・ザ・イヤーになる
  • AmgenのAmjevitaはAbbVie's Humiraの初のバイオシミラーを認可
  • Samsung Bioepisが欧州にバイオシミラーの企業を設立
  • EU CHMP OKのImraidi、SamsungのAbbvieのHumiraのBioepisバイオシミラー
  • AmgenのバイオシミラーAdalimumabが欧州に初めて投入されたが参入はしていない

特許

収益機会

治験動向

参考文献

付録

図表

目次
Product Code: DMKC0189155

This Market Spotlight report covers the Hidradenitis Suppurativa market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

All of the approved drugs for hidradenitis suppurativa (HS) target tumor necrosis factor-alpha. These therapies are administered via the subcutaneous route, while Humira is also available in an intravenous formulation.

The majority of industry-sponsored drugs in active clinical development for HS are in Phase II. Therapies in development for HS target tumor necrosis factor-alpha, interleukin-17, interleukin-1, interleukin-23, JAK/STAT, cluster of differentiation 40, and the C5a receptor. These therapies are administered via the oral, intravenous, and subcutaneous routes.

High-impact upcoming events for drugs in the HS space comprise topline Phase II trial results for Avacopan and Iscalimab. The overall likelihood of approval of a Phase I dermatology-general asset is 25.2%, and the average probability a drug advances from Phase III is 75%. Drugs, on average, take 8.1 years from Phase I to approval in the dermatology-general space, as well as in the overall dermatology space.

There have been only eight licensing and asset acquisition deals involving HS drugs during 2015-20. The $750m definitive agreement signed in December 2019 between Janssen Pharmaceutical and Xbiotech, under which Janssen Pharmaceutical has acquired all rights to Xbiotech's bermekimab, an anti-IL-1alpha monoclonal antibody (mAb) in Phase II development for the treatment of atopic dermatitis and HS, was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for HS have been in the early and midphases of development, with 83% of trials in Phase I-II, and only 17% in Phase III-IV.

The US has the lead in terms of the number of HS clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.

AbbVie and Abbott have the highest number of completed clinical trials for HS, with two trials each.

AbbVie is the only sponsor to have initiated a Phase III and Phase IV trial in HS.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • IFX-1 for HS (November 6, 2019)
  • IFX-1 for HS (July 18, 2019)
  • IFX-1 for HS (June 5, 2019)
  • SensoReady Injector Pen for HS (April 9, 2019)
  • Bermekimab for HS (January 23, 2019)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Janssen Licenses Global Rights To XBiotech's Bermekimab

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Overview of pipeline drugs for HS in the US
  • Figure 2: Pipeline drugs for HS, by company
  • Figure 3: Pipeline drugs for HS, by drug type
  • Figure 4: Pipeline drugs for HS, by classification
  • Figure 5: IFX-1 for HS (June 5, 2019): Phase IIb - SHINE
  • Figure 6: Bermekimab for HS (January 23, 2019): Phase II - Open Label
  • Figure 7: Key upcoming events in HS
  • Figure 8: Probability of success in the HS pipeline
  • Figure 9: Licensing and asset acquisition deals in HS, 2015-20
  • Figure 10: Clinical trials in HS
  • Figure 11: Top 10 drugs for clinical trials in HS
  • Figure 12: Top 10 companies for clinical trials in HS
  • Figure 13: Trial locations in HS
  • Figure 14: HS trials status
  • Figure 15: HS trials sponsors, by phase

LIST OF TABLES

  • Table 1: Marketed drugs for HS
  • Table 2: Pipeline drugs for HS in the US
  • Table 3: IFX-1 for HS (November 6, 2019)
  • Table 4: IFX-1 for HS (July 18, 2019)
  • Table 5: IFX-1 for HS (June 5, 2019)
  • Table 6: SensoReady Injector Pen for HS (April 9, 2019)
  • Table 7: Bermekimab for HS (January 23, 2019)
  • Table 8: Parent patents in HS
  • Table 9: Historical global sales, by drug ($m), 2014-18
  • Table 10: Forecasted global sales, by drug ($m), 2020-24